Lipopolysaccharide, a TLR4 ligand, provides pro-survival signals to cancer cells, thereby inducing therapy resistance [4, 5], whereas a synthetic double-stranded RNA (dsRNA) poly(I:C), a ligand for membrane-bound TLR3, shows direct antitumor effects on a variety of cancers [6–8]. This evidence concerns the gene TLR3 and cancer.